Search

Displaying results 5881 - 5890 of 6279 in total
  1. Drug

    Proscillaridin

    go.drugbank.com/drugs/DB13307
    Experimental

    Studies suggest the potential cytotoxic and anticancer property of proscillaridin, based on evidence of the drug potently disrupting topoisomerase I and II activity at nanomolar drug concentrations [A27193

  2. Drug

    N,N-dimethylarginine

    go.drugbank.com/drugs/DB01686
    Experimental

    It is a metabolic by-product of continual protein modification processes in the cytoplasm of all human cells which is closely related to L-arginine, a conditionally-essential amino acid.

    Synonyms: L-NG,NG-dimethylarginine, N(G),N(G)-Dimethylarginine
  3. Drug

    S-Hydroxycysteine

    go.drugbank.com/drugs/DB01915
    Experimental

    It targets the proteins subtilisin BPN', glutathione S-transferase A1, glutathione S-transferase p, myelin P2 protein, and complement c3.

  4. Drug

    3'-phospho-5'-adenylyl sulfate

    go.drugbank.com/drugs/DB02902
    Experimental

    It is formed from sulfate ion and ATP in a two-step process. This compound also is an important step in the process of sulfur fixation in plants and microorganisms.

  5. Drug

    Octacosanol

    go.drugbank.com/drugs/DB11220
    InvestigationalNutraceutical

    It has been studied as a potential therapeutic agent for the treatment of Parkinson's disease.

  6. Drug

    Bafilomycin A1

    go.drugbank.com/drugs/DB06733
    Experimental

    This is a useful tool as it can prevent the re-acidification of synaptic vesicles once they have undergone exocytosis.

  7. Drug

    NTx-265

    go.drugbank.com/drugs/DB05649
    Investigational

    It is also investigating use of the compound for neurodegenerative disorders, such as Huntington’s disease and Alzheimer’s disease.

  8. Drug

    DP-VPA

    go.drugbank.com/drugs/DB05821
    Investigational

    DP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure frequency.

  9. Drug

    Eprodisate

    go.drugbank.com/drugs/DB06405
    Investigational

    Eprodisate slows the decline of renal function in AA amyloidosis.

  10. Drug

    TTP889

    go.drugbank.com/drugs/DB05131
    Investigational

    TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders. TTP889 is the only known selective small molecule inhibitor of...